Clinical Trial Update: Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating cadonilimab in combination with anti-angiogenic agents for metastatic colorectal cancer with dMMR/MSI-H status; currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Fudan University | Conditions: Colo-rectal Cancer, MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers | Phase 2 | Status: RECRUITING